On September 20, 2021, the Icelandic pharmaceutical company Alvotech made a significant announcement regarding its Biologics License Application (BLA) for AVT02. This product, which Alvotech has developed as a high concentration, interchangeable biosimilar to HUMIRA (adalimumab), has had its resubmitted application accepted by the U.S. Food and Drug Administration (FDA).
This piece of news carries considerable weight for AVT02, and indeed for the field of biotech as a whole, since it could serve as a watershed moment for high concentration biosimilars within the U.S. pharmaceutical market. The FDA has, in turn, set a Biosimilar User Fee Act (BsUFA) goal date for approval of the resubmitted AVT02 BLA for February 24, 2024.
HUMIRA (adalimumab) is a popular and proven treatment option used by healthcare professionals worldwide within a wide range of treatment areas, including rheumatoid arthritis, psoriasis, and Crohn’s disease. Alvotech’s AVT02 aimed at being a biosimilar product, could potentially offer a more affordable option for patients, without sacrificing the effectiveness of the treatment.
Therefore, the approval, or possible rejection, of AVT02’s Biologics License Application by the FDA will hold a considerable amount of interest to legal and healthcare professionals. Not only could it affect Alvotech’s business strategy moving forward, but it will likely prompt discussions on the broader applications and possibilities of biosimilar products within the U.S., and possibly the global healthcare sector.
With the Biosimilar User Fee Act goal date set for 2024, the coming years will undoubtedly see increased debate and discussion around this key regulatory topic. Legal professionals within the pharmaceutical sector are advised to keep a close eye on this development and its potential implications in the field.